Clayman Michael D. 4
4 · Flexion Therapeutics Inc · Filed Jun 28, 2021
Insider Transaction Report
Form 4
Clayman Michael D.
DirectorPresident and CEO
Transactions
- Award
Common Stock
2021-06-21$7.78/sh+1,700$13,226→ 348,840 total
Holdings
- 24,600(indirect: By Trust)
Common Stock
- 388,683(indirect: By LLC)
Common Stock
- 373,769(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]This Form 4 is being filed voluntarily to report the acquisition of 1,700 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan.
- [F2]Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.